Earl St Rose
Overview
Explore the profile of Earl St Rose including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinez F, Rabe K, Ferguson G, Wedzicha J, Singh D, Wang C, et al.
Am J Respir Crit Care Med
. 2020 Nov;
203(5):553-564.
PMID: 33252985
In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF)...
2.
Rabe K, Martinez F, Ferguson G, Wang C, Singh D, Wedzicha J, et al.
N Engl J Med
. 2020 Jun;
383(1):35-48.
PMID: 32579807
Background: Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose...
3.
De Backer W, De Backer J, Verlinden I, Leemans G, Van Holsbeke C, Mignot B, et al.
Ther Adv Respir Dis
. 2020 May;
14:1753466620916990.
PMID: 32380894
Background: Functional respiratory imaging (FRI) is a quantitative postprocessing imaging technique used to assess changes in the respiratory system. Using FRI, we characterized the effects of the long-acting muscarinic antagonist...
4.
Rabe K, Martinez F, Ferguson G, Wang C, Singh D, Wedzicha J, et al.
Respir Med
. 2019 Oct;
158:59-66.
PMID: 31605923
Background: Single inhaler triple therapies providing an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting β-agonist (ICS/LAMA/LABAs) are an emerging treatment option for chronic obstructive pulmonary disease (COPD). Nevertheless,...
5.
Pudi K, Feldman G, Fakih F, Mack P, Maes A, Siddiqui S, et al.
J Aerosol Med Pulm Drug Deliv
. 2018 Oct;
32(1):40-46.
PMID: 30335559
Background: GFF MDI is a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler formulated using co-suspension delivery technology. This open-label, single-arm multicenter study (NCT02268396) evaluated the accuracy, reliability, and functionality of...
6.
Miller S, Nyberg J, Siddiqui S, Dorinsky P, St Rose E, Reisner C
Allergy Asthma Proc
. 2018 Jul;
39(5):350-358.
PMID: 30037361
Background: This is the first study of the inhaled corticosteroid, budesonide, delivered by metered-dose inhaler (BD MDI) using innovative co-suspension delivery technology in adults with asthma. Objective: To characterize the...
7.
Reisner C, Pearle J, Kerwin E, St Rose E, Darken P
Int J Chron Obstruct Pulmon Dis
. 2018 Jun;
13:1965-1977.
PMID: 29950826
Purpose: To determine the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI 36/9.6, 36/7.2, 18/9.6, 9/9.6 µg) using innovative co-suspension delivery technology, compared with glycopyrrolate (GP) MDI...
8.
Fukushima Y, Nakatani Y, Ide Y, Sekino H, St Rose E, Siddiqui S, et al.
Int J Chron Obstruct Pulmon Dis
. 2018 Apr;
13:1187-1194.
PMID: 29695902
Purpose: Due to the burden of COPD in Japan, new pharmacologic treatments are needed to meet patient requirements. This study assessed the efficacy and safety of glycopyrronium (GP) delivered via...
9.
Darken P, DePetrillo P, Reisner C, St Rose E, Dorinsky P
Pulm Pharmacol Ther
. 2018 Mar;
50:11-18.
PMID: 29544728
The budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) is an inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β-agonist fixed-dose combination formulated with innovative co-suspension delivery technology that is in clinical development for...
10.
Kerwin E, Spangenthal S, Kollar C, St Rose E, Reisner C
Respir Res
. 2018 Mar;
19(1):38.
PMID: 29506504
Background: Long-acting muscarinic antagonist (LAMA) and long-acting β-agonist (LABA) bronchodilators are key to the pharmacologic treatment of chronic obstructive pulmonary disease (COPD). This Phase IIb study investigated the safety and...